What are the advantages of UroLift®?

Written by: Mr Michael Wanis
Published: | Updated: 26/05/2023
Edited by: Conor Dunworth

In his latest article renowned consultant urological surgeon and andrologist Mr Michael Wanis explains the revolutionary new treatment for benign prostatic hyperplasia, UroLift®. Mr Wanis offers insight into the benefits of this treatment, what the procedures entails, and who is a good candidate for it. 

 

What is UroLift®, and how does it work to treat Benign Prostatic Hyperplasia (BPH)?

UroLift® is a minimally invasive treatment for patients with obstructive urinary symptoms due to benign prostatic hyperplasia (BPH) also known as an enlarged prostate. The benefit of this technique is to relieve symptoms whilst preserving sexual function including erections and ejaculatory function.

It works by using small titanium implants to hold the prostate lobes apart, relieving pressure on the urethra and allowing the urine to flow more freely and the bladder to empty satisfactorily. This is done via a cystoscope which is a small telescope that is inserted into the urethra (water-pipe). The procedure can be carried out under either a short general anaesthetic or local anaesthetic and patients are usually able to go home on the day of surgery without a catheter. It is associated with a quick recovery time and patients can usually return to work after one week.

 

How long does a UroLift® procedure take, and is it painful?

A UroLift® usually takes under an hour to complete including anaesthetic time. The procedure time varies depending on the size of the prostate gland and the complexity of the case. If it is carried out under local anaesthetic, a nerve block is performed to numb the prostate, and patients may report mild to no discomfort during the procedure.

 

What are the potential risks and complications associated with UroLift®?

While UroLift® is considered a safe procedure with a low risk of complications there are some potential risks and complications to be aware of:

  • Urinary symptoms (transient): After the procedure it is common to experience some mild burning or increased frequency of urination, or mild blood in the urine, which are transient and usually resolve within two weeks. The patient will be given pain relieving medication and sometimes a short course of antibiotics to take home.
  • Urinary tract infection: There is a small risk of developing a urinary tract infection after the procedure, although this is uncommon and usually resolves with antibiotics.
  • Urinary retention: occasionally, the UroLift® implants may cause temporary urinary retention, which can be managed with a temporary catheter.
  • Need for re-treatment: about 1 in 8 men will have some unresolved symptoms and require further treatment either in the form of medication or another procedure at 5 years.
  • Device-related complications (rare): rarely, the UroLift® implants may become dislodged or migrate, and this can usually be corrected with further treatment.

 

How effective is UroLift® compared to other BPH treatments like medication or surgery?

UroLift® is an effective treatment for BPH in carefully selected patients. Several studies have shown that it can provide significant relief from symptoms and improve quality of life for many patients whilst preserving continence and sexual function.

Compared to medications used to treat BPH, UroLift® has been shown to provide more significant and longer-lasting symptom relief with fewer side effects. Medications such as alpha-blockers (e.g. tamsulosin and alfuzosin) typically work by relaxing the muscles around the bladder neck and prostate to improve urine flow, but they may cause side effects such as dizziness, headache, or sexual dysfunction.

 

In comparison to traditional surgery such as transurethral resection of the prostate (TURP), UroLift® is a less invasive option with a lower risk of complications and a quicker recovery time. While TURP is effective at relieving symptoms of BPH, it is associated with a longer hospital stay, a higher risk of bleeding, and a longer recovery period. Overall, UroLift® may be a good option for patients with moderate to severe symptoms of BPH who are looking for a minimally invasive treatment with a low risk of complications and a quick recovery time. It is important that patients carefully discuss the different options available with a urologist and the choice of treatment should be based on the individual needs and preferences of the patient.

In my practice, I sometimes use a patient decision aid to help my patients decide on which treatment suits them best.

 

Who is a good candidate for UroLift®, and who might not be suitable for this procedure?

UroLift® is a suitable treatment option for many men with symptoms of BPH. However, not all patients are good candidates for this procedure.

I typically assess all my patients who are considering UroLift® in the clinic with a uroflow (to objectively measure the strength of their flow), flexible cystoscopy (to assess the prostate anatomy and bladder neck), a prostate volume measurement (using trans rectal ultrasound). Good candidates for UroLift® typically have:

 

  • Moderate to severe symptoms of BPH, such as urinary frequency, urgency, weak stream, and incomplete emptying of the bladder.
  • A prostate gland size of less than 80 grams.
  • A prostate with obstructing lateral lobes without a large middle lobe or high bladder neck
  • A desire to avoid or reduce the use of medications for BPH.
  • A desire for a minimally invasive procedure with a quick recovery time.

 

On the other hand, patients who may not be suitable for UroLift® include those who have:

  • A very large prostate gland size (greater than 80 grams) or prostate cancer.
  • A history of prostate surgery or radiation therapy.
  • A history of urethral stricture or other urethral abnormalities.
  • A history of bladder or urinary tract surgery.
  • A history of blood clotting disorders or taking blood-thinning medications (these need to be stopped temporarily prior to the procedure).

 

Mr Michael Wanis is a leading consultant urological surgeon and andrologist based in Ashtead and Horley, with over a decade of experience. If you would like to book a consultation with Mr Wanis you can do so today via his Top Doctors profile.

By Mr Michael Wanis
Urology

Mr Michael Wanis is a leading Consultant Urological Surgeon and Andrologist based in Ashtead and Horley who specialises in kidney stoneserectile dysfunction and foreskin problems, haematuria (blood in urine)Rezūm and Urolift®. He practices privately at Ashtead Hospital, Spire Gatwick Park Hospital with his NHS base in Surrey and Sussex Healthcare NHS Trust.

After qualifying from the University of Manchester in 2011, Mr Wanis completed his urology specialist training in the Surrey and Sussex region. He went on to complete the necessary examinations to become a Fellow of the Royal College of Surgeons in 2020 and was subsequently appointed as a consultant at Surrey and Sussex Healthcare NHS Trust. Mr Wanis is currently the Urological Cancer Lead at the Trust as well as delivering the andrology service.

Mr Wanis has a specialist interest in kidney stones, male sexual health, urological cancer and minimally-invasive surgery for benign prostate enlargement. He has always had a keen interest in medical education and is passionate about transferring his knowledge onto the next generation. During his specialist training he was awarded the title of Honorary Clinical Lecturer at Brighton and Sussex Medical School for his extensive involvement in undergraduate education. He regularly lectures medical students and junior doctors, is a regular OSCE examiner and has organised national courses for urology trainees including a National Urology ST3 Interview Preparation course endorsed by Health Education England in 2021.

Alongside his work in the UK, Mr Wanis has a passion for global healthcare. Since 2018 he has been the urology lead for the Canadian Coptic Medical Association, a charity organisation which deploys clinicians to Egypt and other African nations, providing education to local doctors and nurses and free treatment to patients living on the poverty line. After receiving the BAUS Urolink Travel award in 2019, he travelled to Tanzania to provide education and training to local urologists.

His research has been published in various peer-reviewed journals and he is also a peer reviewer for the JCU and JELEU journals. He has also presented his research at several prestigious international conferences including the EAU, BAUS and AUA. Mr Wanis is also a member of the British Association of Urological Surgeons, the European Association of Urology and the American Urological Association.

View Profile

Overall assessment of their patients


  • Related procedures
  • Sexually transmitted infections (STIs)
    Vaginoplasty
    Penis Enlargement (Phalloplasty)
    Adult circumcision
    Laparoscopy
    Urologic Oncology
    Geriatric Urology
    Kidney transplantation
    Phimosis
    Short frenulum
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.